Methods of treating tinnitus using oxytocin derivatives
By administering a combination of oxytocin derivative merotocin and mucosal adhesion polymers intranasally, the problem of poor efficacy in existing tinnitus treatments has been solved, resulting in significant tinnitus relief and improved quality of life.
Patent Information
- Application Number
- CN202580014020.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-08
- Filing Date
- 2025-02-07
- Publication Date
- 2026-11-17
AI Technical Summary
Existing tinnitus treatments such as masking, sound therapy, electrical stimulation, and chemotherapy fail to provide satisfactory relief, impacting patients' quality of life.
Using the oxytocin derivative merotocin, delivered in powder or nebulized form via intranasal or epinasal administration, combined with mucosal adhesion polymers and salts, at specific doses and time intervals, a pharmaceutical composition is formed to treat tinnitus.
It significantly reduces tinnitus-related symptoms, improves patients' quality of life, reduces side effects, enhances treatment efficacy, and reduces the need for multiple daily doses.
Abstract
Description
[0001] Copyright Notice
[0002] This patent document contains a portion of copyrighted material. The copyright holder does not object to any fax reproduction of this patent document or the patent disclosure (as it appears in the patent documents or records of the Patent and Trademark Office), but otherwise reserves all copyright rights.
[0003] Cross-references to related applications
[0004] This application claims priority to U.S. Provisional Application No. 63 / 551,485, filed February 8, 2024, entitled “METHODS OF TREATMENT OF TINNITUS”, the disclosure of which is incorporated herein by reference in its entirety.
[0005] This application relates to the following patents, which are incorporated herein by reference in their entirety:
[0006] U.S. Patent Application No. 17 / 007,518, entitled “OXYTOCIN COMPOSITIONS FOR TREATMENT OF TINNITUS”, was filed on August 31, 2020, and granted as U.S. Patent No. 11,241,477 on February 8, 2022.
[0007] sequence list
[0008] The sequence list conforming to WIPO standard ST.26 is incorporated herein by reference. The sequence list was submitted as an electronic document via PatentCenter in UTF-8 text-encoded XML. This electronic document was created on February 8, 2024, with the title “058636.00303_ST26.xml” and a size of 1,797 bytes. Background Technology
[0009] Tinnitus is the sensation of noise or ringing in the ear. Tinnitus is usually a subjective perception, meaning only the affected person can perceive the sound. Perceived sensations can include ringing, booming, static noise, buzzing, hissing, and whistling in one or both ears. The noise can be intermittent or continuous. It is estimated that approximately 15% to 20% of people experience some degree of tinnitus. Severe or chronic tinnitus can impact the quality of life for patients and their families. Tinnitus can lead to depression and anxiety problems. Current treatments include masking, sound therapy, electrical stimulation, and chemotherapy. However, these treatments do not provide satisfactory relief, and therefore more effective treatments still need to be developed. Summary of the Invention
[0010] In one embodiment, a method for treating tinnitus is disclosed. The method includes administering 50 to 260 IU of merotocin to an individual requiring treatment over a 24-hour period. The method may include intranasal administration of merotocin or administration of merotocin in powder or nebulized form to the upper nasal cavity of the individual. The method may include merotocin administered in a composition further comprising a thickener present in an amount of 5% to 12% by weight of the composition, wherein the viscosity of the thickener is 4,000 to 12,000 cps. The composition may also contain a mucosal adhesion polymer. Merotocin may be delivered in 3 to 5 doses over a 24-hour period, wherein each dose delivers 12 to 665 IU of merotocin. The method may also include administration of merotocin in a solution suitable for parenteral administration.
[0011] In another embodiment, a pharmaceutical composition for treating tinnitus is disclosed, comprising about 50 to 260 IU of merotocin / ml. The pharmaceutical composition also comprises a thickener present in an amount of 5% to 12% by weight of the composition, said thickener having a viscosity of about 4,000 to 12,000 cps. The pharmaceutical composition can be administered to an individual's upper nasal cavity in powder or nebulized form. The pharmaceutical composition may also comprise a mucosal adhesion polymer, and magnesium chloride, citric acid, or sodium citrate. The pharmaceutical composition can be delivered in 3 to 5 doses over a 24-hour period and is suitable for parenteral administration.
[0012] In another embodiment, a sprayable unit dose for treating tinnitus is disclosed, the sprayable unit dose being formulated for intranasal administration and containing 15 to 65 IU of merotocin. The sprayable unit dose may also contain a thickener present in an amount of about 5% to 12% by weight, wherein the viscosity of the thickener is about 4,000 to 12,000 cps. The sprayable unit dose may contain a volume of 0.05 to 0.15 ml and may be delivered 3 to 5 times over a 24-hour period. The sprayable unit dose may also contain magnesium chloride, citric acid, or sodium citrate.
[0013] The foregoing summary is merely illustrative and is not intended to be limiting in any way. Other aspects, implementations, and features, in addition to the illustrative aspects, implementations, and features described above, will become apparent from the following detailed description. Detailed Implementation
[0014] This disclosure provides compositions and methods for treating tinnitus. The composition comprises a therapeutically effective dose of oxytocin for intranasal administration. The method comprises administering the composition containing a therapeutically effective dose of oxytocin intranasally to an individual requiring treatment. The therapeutically effective dose may be delivered in one or more doses.
[0015] Oxytocin is a nine-amino acid cyclic peptide hormone containing two cysteine residues forming a disulfide bridge between positions 1 and 6. The amino acid sequence of human oxytocin is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly (SEQ ID NO:1). The oxytocin peptide used in the methods of this invention can be natural or synthetic, or can be produced by recombinant technology. Oxytocin is also commercially available.
[0016] Peptide analogs and derivatives of oxytocin are known in the art and can be used in the methods of the present invention. Some examples of oxytocin analogs include 4-threonine-1-hydroxy-deaminooxytocin, 4-serine, 8-isoleucine-oxytocin, 9-deamidooxytocin, 7-D-proline-oxytocin and its deamino analogs, (2,4-diisoleucine)-oxytocin, deaminooxytocin analogs, 1-deamino-1-monocarba-E12-Tyr(OMe)]-OT (dCOMOT), carbetocin, 4-threonine, 7-glycine-oxytocin (TG-OT), oxytocin, deamino-6-carba-oxytocin (oxytoxin) (dC60), L-371,257, and related compounds containing an o-trifluoro(-trigluoro)-ethoxyphenylacetyl core, such as L-374,943. Another example of an oxytocin derivative that can be used in the method of the present invention is merotocin, also known as carba-1-(4-FBzlGly7)dOT. Merotocin can be named compound FE 202767, and is also known as glycineamide, N-(4-mercapto-l-oxobutyl)-L-tyrosino-L-isoleucyl-L-glutamine acyl-L-asparaginyl-L-cysteyl-N-[(4-fluorophenyl)methyl]glycine-L-leucyl-, cyclic (1, )-Thioether or [Bual,4-FBzlGly7] oxytocin. Further information regarding merotocin can be found in Ferring's U.S. Patent Application Publication 2022 / 0313774 (the description of merotocin is incorporated herein by reference). Further examples of oxytocin analogues can be found in Cai's U.S. Patent Application Publication 2014 / 0066373 and Ferring's U.S. Patent No. 8,673,841 (the descriptions of their analogues are both incorporated herein by reference).
[0017] Oxytocin or its analogues may be chemically modified, for example by amidation, the use of D amino acids in the peptide, incorporation of small non-peptide moieties, and modification of the amino acids themselves (e.g., alkylation or esterification of R groups in the side chain). Such analogues, derivatives, and fragments should at least substantially retain the desired biological activity of the natural oxytocin peptide of SEQ ID NO:1. For example, in some embodiments, such analogues may retain at least 70%, at least 80%, at least 90%, or at least 95% of the oxytocin activity of SEQ ID NO:1.
[0018] Clinical practice and trials have revealed several aspects in which the use of oxytocin analogues and derivatives, particularly merotocin, may be more effective than oxytocin in treating tinnitus. Some advantages of using oxytocin analogues or derivatives, such as merotocin, in the methods of this invention include the following: oxytocin analogues and derivatives (a) can be modified to be temperature-stable, thereby ensuring consistent efficacy of the drug even at room temperature and eliminating the need for continuous refrigeration; (b) have a longer half-life than oxytocin, thereby reducing the need for multiple daily doses; (c) can be administered in forms other than nasal sprays, such as as powder or nebulized formulations, or as solutions suitable for parenteral administration; and (d) target only the oxytocin V1 receptor, thereby eliminating the possibility of off-target side effects.
[0019] As used herein, the term "treatment" refers to the reduction of one or more symptoms or features associated with the presence of the specific condition being treated. Treatment does not necessarily imply a complete cure or relief, nor does it preclude recurrence or relapse. For example, in this disclosure, treatment means the reduction of one or more symptoms associated with tinnitus. Treatment may target symptoms, for example, suppressing symptoms. It may be short-term, medium-term, or long-term, such as in the case of maintenance therapy. Application may be intermittent, periodic, or continuous.
[0020] As used herein with respect to a single agent, the term "therapeutic effective amount" refers to an amount sufficient to achieve the intended therapeutic purpose in one or more doses. The exact amount desired or required will vary depending on the specific compound or composition used, its administration method, patient details, etc. A suitable effective amount can be determined by those skilled in the art based on what is known from this disclosure.
[0021] Where numerical ranges are provided in this disclosure, it should be understood that, unless otherwise expressly stated, all intermediate values between the upper and lower limits of the range, up to the tenth of the lower limit, and all intermediate ranges are covered within this invention.
[0022] Nouns without quantifiers also include their plural referents, and vice versa.
[0023] The compositions of this invention can be delivered intranasally. As used herein, the term “intranasal delivery” means that the composition or active agent (e.g., oxytocin) is delivered into the nose, nasal passage, or nasal cavity. Oxytocin or compositions containing oxytocin may be in the form of a spray, drops, powder, suspension, gel, inhaler, nebulizer, or any other suitable form.
[0024] Compositions containing oxytocin can be prepared for pharmaceutical use by combination with a pharmaceutically acceptable carrier or diluent. The compositions can be formulated for intranasal delivery. Formulations may contain excipients, carriers, emulsifiers, stabilizers, preservatives, mucosal adhesives, antibacterial agents, buffers, and / or other additives. Common pharmaceutical formulation components and preparation methods can be found in Remington's Pharmaceutical Sciences, 2000, 20th edition.
[0025] In one embodiment, the oxytocin formulation used in the method of the present invention can be in powder (e.g., dry powder) form, liquid-based form, or atomized form. When used in powder form, the powder can be substantially pure oxytocin (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, or 99%), or may contain other components, such as salts. In one embodiment, the powder can be 94% to 99% pure oxytocin. When used in liquid-based or atomized form, the composition may contain salts and buffers, and optionally a thickener. The composition may also optionally contain excipients, carriers, etc. Oxytocin can be present as incorporated nanoparticles (including liposomes).
[0026] In one embodiment, the oxytocin preparation may be liquid-based or atomized and contains a magnesium salt, such as magnesium chloride or magnesium citrate.
[0027] In one embodiment, oxytocin is present as a sprayable composition. The sprayable composition (which may also be delivered as drops or atomized form) may comprise oxytocin and a salt, or consist essentially of oxytocin and a salt. In one embodiment, the composition comprises, consists essentially of, or consists of oxytocin, a magnesium salt, sodium citrate, and citric acid. In one embodiment, the composition further comprises a mucosal adhesion polymer. The sprayable composition can be delivered using a sprayer. The sprayer may include an operating device (e.g., a nozzle or pump) in fluid communication with a reservoir. The spraying device may be manually actuated or pressurized.
[0028] The amount of oxytocin can be from 100 to 600 IU / ml of the composition. In one embodiment, the amount of oxytocin per ml can be from 150 to 450 IU. In many embodiments, the amount of oxytocin can be 150, 200, 250, 300, 350, 400, or 450 IU / ml.
[0029] Magnesium salts can be any pharmaceutically acceptable magnesium salt. Some examples include magnesium chloride, magnesium citrate, magnesium acetate, etc.
[0030] "Mucosal adhesive" (also referred to herein as "thickener") generally refers to a compound that adheres to the surface of a mucosa. Mucosal adhesives can be polymers, such as anionic polymers (e.g., alginate, xanthan gum, carrageenan), cationic polymers (e.g., chitosan), nonionic polymers (e.g., guar gum), amphoteric polymers, synthetic polymers, etc. In one embodiment, the mucosal adhesive polymer is Mucolox™. These agents typically increase the viscosity of the composition. In one embodiment, the viscosity of the mucosal adhesive can be from 4,000 to 12,000 cps. In one embodiment, the viscosity of the mucosal adhesive is from 5,000 to 10,000 cps. In many embodiments, the viscosity of the mucosal adhesive can be 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, or 11,000 cps.
[0031] In one embodiment, the composition of the present invention is present in a sprayable unit dose for intranasal administration, comprising or substantially consisting of 15 to 65 IU of oxytocin per unit dose. In another embodiment, the composition of the present invention is present in a sprayable unit dose for intranasal administration, comprising or substantially consisting of 15 to 65 IU of oxytocin per unit dose and a thickener present in an amount of about 5% to 12% by weight of the composition, wherein the viscosity of the thickener is about 4,000 to 12,000 cps. In one embodiment, the unit dose may comprise 20, 25, 30, 35, 40, 45, 50, 55, or 60 IU of oxytocin. The unit dose may be 0.05 to 0.15 ml. In some embodiments, the unit dose may be 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, or 0.15 ml. In one implementation, the unit dose is approximately 0.1 ml.
[0032] In one embodiment, this disclosure provides a pharmaceutical composition for intranasal administration comprising or substantially consisting of: a) 100 to 600 IU of oxytocin / ml, optionally, b) a thickener present in an amount of 5% to 12% by weight of the composition, wherein the viscosity of the thickener is about 4,000 to 12,000 cps; and optionally, c) magnesium chloride, citric acid, and sodium citrate.
[0033] In one embodiment, this disclosure provides a pharmaceutical composition suitable for intranasal administration, comprising oxytocin and a thickener (viscosity modifier) present in an amount of about 1% to about 15% by weight of the composition. The thickener (e.g., Mucolox™) may be present in an amount of 5% to 12% (viscosity of 4,000 to 12,000 cps). Oxytocin may be present in an amount of 0.05% to 0.1% by weight. The oxytocin concentration may be 100 to 600 IU / ml. The composition may contain a salt (e.g., magnesium salt, zinc salt, sodium salt, etc.) and a buffer. In one embodiment, the composition may contain oxytocin present in an amount of 0.05% to 0.1% by weight; a thickener present in an amount of about 5% to 12% by weight, said thickener having a viscosity of about 4,000 to 12,000 cps; and one or more salts or buffers.
[0034] In one embodiment, oxytocin is present in powder form. In the powder formulation, oxytocin may be delivered as the sole component, or other components (e.g., magnesium or zinc salts) may be mixed with the powder. Dry powder forms of oxytocin are known in the art (see, for example, Fabio et al., AAPS PharmSciTech, Vol. 16, No. 6, 1299-1306, 2015, incorporated herein by reference). For example, oxytocin powder formulations for inhalation may contain excipients and stabilizers such as trehalose, isoleucine, polyvinylpyrrolidone, citrates (sodium citrate and citric acid), and zinc salts (e.g., zinc chloride and zinc citrate).
[0035] In one embodiment, the nasal spray formulation can be prepared as follows: for a total volume of 38.0 ml, 0.3080 g of oxytocin powder, 2.3 g of magnesium chloride, 0.1080 g of anhydrous citric acid granules, 2.15 g of sodium citrate powder, 3.8 ml of PCCAMucolox™ liquid, and the remainder being water (Formulation 1). This provides 45 IU units of oxytocin per 0.1 ml nasal spray.
[0036] In another embodiment, the formulation can be prepared as follows: for a total volume of 30.0 ml, 0.45 g of oxytocin 10 IU / mg ground powder, 1.83 g of magnesium chloride crystals, 0.0860 g of anhydrous citric acid granules, 1.7 g of sodium citrate powder, 3.0 ml of PCCA Mucolox™ liquid, and the remainder being water (Formulation 2). This provides a 15 IU oxytocin / 0.1 ml nasal spray.
[0037] According to one embodiment, this disclosure provides a method for treating tinnitus. The method includes administering intranasal administration of a composition comprising oxytocin or substantially oxytocin to an individual, wherein such administration produces treatment of the tinnitus. The effectiveness of the tinnitus treatment can be monitored by quantifying the tinnitus, for example, through self-assessment using clinically acceptable techniques. One example is the Tinnitus Handicap Inventory (THI), a validated and published measurement technique (Newman et al., Arch Otolaryngol Head Neck Surg, 1996, February 122(2), 143-8). In one embodiment, improvement in an individual using the THI may include at least a 10% improvement. In several embodiments, improvement may include 10% to 100%, for example at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%.
[0038] In one embodiment, the method includes administering approximately 50 to 260 IU of oxytocin over a 24-hour period. In another embodiment, the method includes delivering approximately 100 to 250 IU, 160 to 240 IU, or 50 to 200 IU over a 24-hour period. In several embodiments, the amount of oxytocin delivered over the 24-hour period can be 50, 75, 100, 125, 150, 175, 200, 225, and 250 IU. The amount of oxytocin delivered over the 24-hour period can be delivered in 2 to 5 doses. In one embodiment, the dose can be 1 to 6 doses or 2 to 6 doses or more. In one embodiment, it is delivered in 3, 4, or 5 doses. Each dose can deliver the same or different amount of oxytocin as the other doses. In one embodiment, each dose can deliver 12 to 65 IU / dose.
[0039] The results of this disclosure were unexpected, as the use of lower doses of oxytocin (e.g., less than 20 IU / day) did not produce any significant relief. The addition of the mucosal adhesion polymer necessitates a lower daily dose and reduces flow-out of the spray composition.
[0040] The compositions of this invention can be delivered to any part of the nasal cavity. In one embodiment, the composition can be delivered to the blood-rich upper nasal cavity. For example, a device specifically designed for delivering the composition to the upper nasal cavity can be used. This allows the active agent to rapidly enter the circulation, and particularly the central nervous system. Devices developed for delivery to the upper nasal cavity include those described in U.S. Patent Nos. 9,550,036 and 9,919,117 to Impel Neuropharma Inc. (incorporated herein by reference). Compositions delivered using these devices can be in liquid form or can be in dry powder form. In one embodiment of delivering the composition to the upper nasal cavity, a mucosal adhesion polymer may not be necessary. In one embodiment, a composition comprising oxytocin and optionally salts and / or buffers, or substantially composed therefrom and without a thickener, can be delivered to the upper nasal cavity. The amount of oxytocin delivered to the upper nasal cavity over a 24-hour period may be less than the amount required if delivered to the external nasal cavity. For example, over a 24-hour period, the oxytocin delivered to the upper nasal cavity can be 50 to 260 IU or 50 to 200 IU, or less than 50 IU, for example, 20 to 200 or 20 to 50 IU over a 24-hour period. In some embodiments, over a 24-hour period, the delivered oxytocin can be 20 to 260 IU, 50 to 250 IU, 50 to 225 IU, 100 to 225 IU, 20 to 225 IU, and all values and ranges between 20 and 260 IU.
[0041] Individuals who can be treated with the compositions of the present invention include those suffering from tinnitus. While the method of the present invention is useful for individuals who suffer from tinnitus but not from migraines, it can also be used for individuals who have tinnitus accompanied by migraines. The compositions of the present invention can be used to treat tinnitus in male subjects and non-pregnant female subjects.
[0042] Example
[0043] The following are some non-limiting embodiments of the implementation of this disclosure.
[0044] Example 1. A method for treating tinnitus, comprising administering 50 to 260 IU of oxytocin intranasally to an individual requiring treatment over a 24-hour period.
[0045] Example 1a. The method of Example 1, wherein 50 to 250, 50 to 225, 50 to 200, 100 to 225, 100 to 250 or 100 to 200 IU of oxytocin are administered to the individual over a 24-hour period.
[0046] Example 1b. The method of Example 1a, wherein 100 to 200 IU or 100 to 225 IU of oxytocin is administered to the individual during the 24-hour period.
[0047] Example 1c. The method of Example 1b, wherein 160 to 200 IU of oxytocin is administered to the individual during the 24-hour period.
[0048] Example 1c.1 The method of Example 1c, wherein approximately 180 IU of oxytocin is administered to the individual during the 24-hour period.
[0049] Example 1d. The method of any of the preceding examples, wherein the oxytocin is delivered in 3, 4 or 5 doses over the 24-hour period.
[0050] Example 1e. The method described in Example 1d, wherein each dose delivers approximately 12 to 65 IU of oxytocin.
[0051] Example 1f. The method of Example 1, wherein the oxytocin delivered in the composition further comprises a thickener present in an amount of 5% to 12% by weight of the composition, the thickener having a viscosity of 4,000 to 12,000 cps.
[0052] Example 1g. The method of Example 1, wherein the application lasts for several days, weeks or months.
[0053] Example 1h. The method described in Example 1, wherein the individual is a male or a postmenopausal female.
[0054] Example 1i. The method described in Example 1, wherein the individual also suffers from migraines.
[0055] Example 1j. The method described in Example 1, wherein the individual does not suffer from migraines.
[0056] Example 2. A sprayable composition for intranasal application comprising about 100 to 600 IU of oxytocin / ml and a thickener present in an amount of 5% to 12% by weight of the composition, the thickener having a viscosity of about 4,000 to 12,000 cps.
[0057] Example 2a. The sprayable composition of Example 2, wherein the composition contains about 150 to 450 IU of oxytocin / ml.
[0058] Example 2b. The sprayable composition of Example 2, wherein the thickener is Mucolox™.
[0059] Example 2c. The sprayable composition of Example 2 further comprises salt and / or buffer.
[0060] Example 3. A sprayable unit dose of oxytocin, formulated for intranasal administration, comprising 15 to 65 IU of oxytocin and a thickener present in an amount of about 5% to 12% by weight of the composition, the thickener having a viscosity of about 4,000 to 12,000 cps.
[0061] Example 3a. The sprayable unit dose of Example 3, wherein the volume of the dose is about 0.05 to 0.15 ml, for example 0.1 ml.
[0062] Example 3b. The sprayable unit dose described in Example 3, wherein the thickener is Mucolox™.
[0063] Example 4. A pharmaceutical composition suitable for intranasal administration, comprising oxytocin and a viscosity modifier present in an amount of about 1% to about 15% by weight of the composition.
[0064] Example 4a. The pharmaceutical composition of Example 4, wherein the viscosity modifier is present in an amount of 5% to 12% Mucolox™.
[0065] Example 4b. The pharmaceutical composition of Example 4 or 4a, wherein oxytocin is present in an amount of 0.05% to 0.1% by weight.
[0066] Example 4c. The pharmaceutical composition of any one of Examples 4 to 4b, further comprising a salt and / or a buffer.
[0067] Example 4d. The pharmaceutical composition of any one of Examples 4 to 4b further comprises magnesium chloride, citric acid and sodium citrate.
[0068] Example 5. A pharmaceutical composition for intranasal administration, comprising or substantially consisting of the following:
[0069] a) Oxytocin present in amounts of 0.05% to 0.1% by weight;
[0070] b) A thickener in an amount of about 5% to 12% by weight, said thickener having a viscosity of about 4,000 to 12,000 cps, and
[0071] c) One or more salts or buffers.
[0072] Example 5a. The pharmaceutical composition of Example 5, wherein the salt or buffer is magnesium chloride, sodium citrate and citric acid.
[0073] Example 6. A pharmaceutical composition for intranasal administration, comprising or substantially consisting of the following:
[0074] a) 100 to 600 IU of oxytocin / ml
[0075] b) A thickener present in an amount of 5% to 12% by weight of the composition, said thickener having a viscosity of about 4,000 to 12,000 cps, and
[0076] c) Magnesium chloride, citric acid, and sodium citrate.
[0077] Example 7. A method for treating tinnitus in an individual, comprising delivering oxytocin in powder or atomized form into the individual's upper nasal cavity.
[0078] Example 7a. The method of Example 7, wherein the oxytocin is delivered in powder form, and the amount of oxytocin delivered over a 24-hour period is about 20 to 200 IU.
[0079] Example 7b. The method described in Example 7a, wherein the oxytocin powder is at least 95% pure oxytocin.
[0080] Example 8. A method for treating tinnitus in an individual, comprising delivering oxytocin in a sprayable composition to the upper nasal cavity of the individual in one or more doses over a 24-hour period, wherein the one or more doses are 20 to 260, 20 to 225, or 20 to 200 IU of oxytocin.
[0081] Example 8a. The method of Example 8, wherein delivery is achieved by pushing the composition into the upper nasal cavity.
[0082] Example 8b. The method of Example 8, wherein the oxytocin composition comprises a mucosal adhesion polymer.
[0083] Example 9. A composition for use in any of the methods from any of the foregoing examples.
[0084] The following embodiments are provided to further illustrate the invention and are not intended to limit it in any way.
[0085] This example describes the clinical use of the formulation of the present invention for the treatment of tinnitus. In a patient suffering from tinnitus, an initial dose of less than 20 IU per day was tried, but this did not provide any relief. A compound formulation of oxytocin was then used, providing a daily dose of 60 IU (30 IU twice daily). The formulation contained oxytocin, magnesium chloride, citric acid, and sodium citrate in sterile water. The patient reported some benefit. The dose was then increased to 45 IU (3 15 IU sprays) four times daily. This produced significant relief. A thickener was then added to the formulation while maintaining the same amount of oxytocin. The patient subsequently reported several days of tinnitus-free periods. His Tinnitus Disability Scale score decreased from 96 points before treatment (meaning a very poor level) to a current score of 14 points (meaning mild or no tinnitus). The patient has continued to improve for more than 1 year since the start of treatment. His current dose is 22.5 IU per nostril four times daily. Because his tinnitus occurred in a distinctly periodic manner, he increased the dosage to five times daily for two days when the tinnitus was at its loudest. Over the past three months, this dosage regimen has reduced the severity of the tinnitus and enabled him to go tinnitus-free for up to 10 days. His current disability scale score is 8.
[0086] In another patient with tinnitus, a twice-daily dose of 45 IU of oxytocin showed significant benefit. This patient reported a 45% to 60% reduction in tinnitus loudness for the first time in years, and also had several days without tinnitus. He continued to improve with this dosing regimen for over a year.
[0087] In another patient with drug-induced tinnitus, a dose of 30 IU twice daily was used without benefit. Increasing the dose to 45 IU four times daily reduced the loudness of the tinnitus by approximately 30%.
[0088] In another patient who developed persistent tinnitus a year after a neck injury, a dose of 45 IU four times daily (22.5 IU in each nostril) was used for 30 days and is still ongoing. This provided approximately 15% improvement. Sometimes, the patient increased the dose to five times daily, resulting in a reduction in the loudness of the tinnitus.
[0089] In another patient suffering from persistent tinnitus, a dose of 30 IU four times daily had been started and treatment was ongoing. Two weeks later, for the first time in three years, he noticed that he could spend several hours each day without perceptible tinnitus, and the intensity of the tinnitus had decreased.
[0090] Although the invention has been described by way of illustrative embodiments, conventional modifications will be apparent to those skilled in the art, and such modifications are intended to fall within the scope of this disclosure. Claims (as amended under Article 19 of the Treaty) 1. A method of treating tinnitus, which involves administering 50 to 260 IU of merotocin to the individual requiring treatment over a 24-hour period. 2. The method of claim 1, wherein the merotocin is administered intranasally. 3. The method of claim 1, wherein the merotocin is in powder or atomized form and is administered to the upper nasal cavity of the individual. 4. The method of claim 1, wherein the merotocin applied to the composition further comprises a thickener present in an amount of 5% to 12% by weight of the composition, the thickener having a viscosity of 4,000 to 12,000 cps. 5. The method of claim 4, wherein the composition further comprises a mucosal adhesion polymer. 6. The method of claim 1, wherein the merotocin is administered in a solution suitable for parenteral administration. 7. The method of claim 1, wherein the merotocin is delivered in 3 to 5 doses over a 24-hour period. 8. The method of claim 7, wherein each dose delivers 12 to 65 IU of merotocin. 9. A pharmaceutical composition for treating tinnitus, said pharmaceutical composition comprising 50 to 260 IU of merotocin / ml and a thickener present in an amount of 5% to 12% by weight of said composition. 10. The pharmaceutical composition of claim 9, wherein the viscosity of the thickener is 4,000 to 12,000 cps. 11. The pharmaceutical composition of claim 9, wherein the composition is in powder or atomized form and is delivered into the upper nasal cavity of an individual. 12. The pharmaceutical composition of claim 9, wherein the composition further comprises a mucosal adhesion polymer. 13. The pharmaceutical composition of claim 9, wherein the composition further comprises magnesium chloride, citric acid, or sodium citrate. 14. The pharmaceutical composition of claim 9, wherein the composition is delivered in 3 to 5 doses over a 24-hour period. 15. The pharmaceutical composition of claim 9, wherein the composition is suitable for parenteral administration. 16. A sprayable unit dose for the treatment of tinnitus, said sprayable unit dose being formulated for intranasal administration and containing 15 to 65 IU of merotocin. 17. The sprayable unit dose of claim 16, wherein the sprayable unit dose further comprises a thickener present in an amount of about 5% to 12% by weight, the thickener having a viscosity of about 4,000 to 12,000 cps. 18. The sprayable unit dose of claim 16, wherein the sprayable unit dose comprises a volume of 0.05 to 0.15 ml. 19. The sprayable unit dose of claim 16, wherein the sprayable unit dose is delivered 3 to 5 times over a 24-hour period. 20. The sprayable unit dose of claim 16, wherein the sprayable unit dose further comprises magnesium chloride, citric acid, or sodium citrate.
Claims
1. A method of treating tinnitus, which involves administering 50 to 260 IU of merotocin to the individual requiring treatment over a 24-hour period.
2. The method of claim 1, wherein the merotocin is administered intranasally.
3. The method of claim 1, wherein the merotocin is in powder or atomized form and is administered to the upper nasal cavity of the individual.
4. The method of claim 1, wherein the merotocin applied to the composition further comprises a thickener present in an amount of 5% to 12% by weight of the composition, the thickener having a viscosity of 4,000 to 12,000 cps.
5. The method of claim 4, wherein the composition further comprises a mucosal adhesion polymer.
6. The method of claim 1, wherein the merotocin is administered in a solution suitable for parenteral administration.
7. The method of claim 1, wherein the merotocin is delivered in 3 to 5 doses over a 24-hour period.
8. The method of claim 7, wherein each dose delivers 12 to 65 IU of merotocin.
9. A pharmaceutical composition for treating tinnitus, said pharmaceutical composition comprising 50 to 260 IU of merotocin / ml and a thickener present in an amount of 5% to 12% by weight of said composition.
10. The pharmaceutical composition of claim 9, wherein the viscosity of the thickener is 4,000 to 12,000 cps.
11. The pharmaceutical composition of claim 9, wherein the composition is in powder or atomized form and is delivered into the upper nasal cavity of an individual.
12. The pharmaceutical composition of claim 9, wherein the composition further comprises a mucosal adhesion polymer.
13. The pharmaceutical composition of claim 9, wherein the composition further comprises magnesium chloride, citric acid, or sodium citrate.
14. The pharmaceutical composition of claim 9, wherein the composition is delivered in 3 to 5 doses over a 24-hour period.
15. The pharmaceutical composition of claim 9, wherein the composition is suitable for parenteral administration.
16. A sprayable unit dose for the treatment of tinnitus, said sprayable unit dose being formulated for intranasal administration and containing 15 to 65 IU of merotocin.
17. The sprayable unit dose of claim 16, wherein the sprayable unit dose further comprises a thickener present in an amount of about 5% to 12% by weight, the thickener having a viscosity of about 4,000 to 12,000 cps.
18. The sprayable unit dose of claim 16, wherein the sprayable unit dose comprises a volume of 0.05 to 0.15 ml.
19. The sprayable unit dose of claim 16, wherein the sprayable unit dose is delivered 3 to 5 times over a 24-hour period.
20. The sprayable unit dose of claim 16, wherein the sprayable unit dose further comprises magnesium chloride, citric acid, or sodium citrate.
Citation Information
Patent Citations
Oxytocin compositions for treatment of tinnitus
US11241477B2
Treating diabetes with oxytocin or oxytocin analogs
US20140066373A1
Oxytocin compositions for treatment of tinnitus
US20210060119A1
Intranasal administration of merotocin for improving lactation
US20220313774A1
Oxytocin analogues
US8673841B2
